BIVI News

In the busiest week yet for the 2020 IPO market, 15 IPOs raised $8.7 billion. Snowflake (SNOW) took the spotlight, completing the largest software IPO ever and bagging the biggest billion-dollar pop in two decades. Eight SPACs joined the week’s diverse group of IPOs. The year’s largest IPO to date, Snowflake (SNOW) priced above...read more

BioVie, a Phase 2 biotech developing therapies for cirrhosis, raised $16 million by offering 1.6 million shares at $10, below the last close of its shares on the OTC (BIVI). The company offered 0.3 million more shares than anticipated. BioVie plans to list on the Nasdaq under the symbol BIVI. ThinkEquity and Kingswood Capital Markets acted as lead managers on the deal. ...read more

BioVie, a Phase 2 biotech developing therapies for cirrhosis, submitted an amendment on Wednesday with the SEC. The blank filing indicates that the company plans to raise up to $18 million in an initial public offering. The company is currently listed on the OTCQB (BIVI) and last closed at $9. In its latest filing, BioVie also removed the attached warrants, removed ThinkEquity...read more

BioVie, an early stage biotech developing therapies for cirrhosis, filed an amended S-1 on Wednesday with the SEC to raise up to $15 million, based on its registered offering of 1.7 million units at $8.75, the as-converted last close of its stock on the OTCQB (BIVI). At that price, it would command a post-offering market cap of $94 million. The company added warrants in the latest...read more